Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery

Bibliography

• Washington C, Washington CG, Wilson CG. Physiological Pharmaceutics. Barriers to Drug Absorption. Taylor and Francis, London; 2001
   Google Scholar
• Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J 2009;11:740-6
   PubMed Web of Science ®Google Scholar
• Daugherty AL, Mrsny RJ. Transcellular uptake mechanisms of the intestinal epithelial barrier. Part one. Pharm Sci Technol Today 1999;8:144-51
   Google Scholar
• Daugherty AL, Mrsny RJ. Regulation of the intestinal epithelial paracellular barrier. Pharm Sci Technol Today 1999;2:281-87
   PubMedGoogle Scholar
• Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 2008;52:2-12
   PubMed Web of Science ®Google Scholar
• Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 2007;117:3173-6
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001;46:89-102
   PubMed Web of Science ®Google Scholar
• Bansal T, Akhtar N, Jaggi M, Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009;14:1067-74
   PubMed Web of Science ®Google Scholar
• Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 2007;59:677-94
   PubMed Web of Science ®Google Scholar
• Cai Z, Wang Y, Zhu LJ, Liu ZQ. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 2010;11:197-207
   PubMed Web of Science ®Google Scholar
• Ponchel G, Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998;34:191-219
   PubMed Web of Science ®Google Scholar
• Arun R, Ashok Kumar CK, Sravanthi VVNSS. Cyclodextrins as drug carrier molecule: a review. Scientia Pharm 2008;76:567-98
   Google Scholar
• Endo T, Nagase H, Ueda H, Isolation, purification and characterization of cyclomaltooctadecaose (nu-cyclodextrin), cyclomaltononadecaose (xi-cyclodextrin), cyclomaltoeicosaose (o-cyclodextrin) and cyclomaltoheneicosaose (pi-cyclodextrin). Chem Pharm Bull 1998;46:1840-43
   Web of Science ®Google Scholar
• Miyazawa I, Ueda H, Nagase H, Physicochemical properties and inclusion complex-formation of delta-cyclodextrin. Eur J Pharm Sci 1995;3:153-62
   Web of Science ®Google Scholar
• McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in-liposomes: a novel concept in drug delivery. Int J Pharm 1994;112:249-58
   Web of Science ®Google Scholar
• McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. J Drug Target 1994;2:449-54
   PubMed Web of Science ®Google Scholar
• Silveira AM, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm Res 1998;15:1051-55
   PubMed Web of Science ®Google Scholar
• Cirpanli Y, Bilensoy E, Lale Dogan A, Calis S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm 2009;73:82-9
   PubMed Web of Science ®Google Scholar
• Agueros M, Zabaleta V, Espuelas S, Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 2010;145:2-8
   PubMed Web of Science ®Google Scholar
• Pecchio M. Development and characterization of cyclosporine A-loaded Gantrez AN 119 nanoparticles for oral delivery. In vivo behaviour. Ph.D. Thesis University of Navarra, Pamplona, Spain; 2010
   Google Scholar
• Calvo J. Nanoparticles as vehicles for the oral delivery of antimalarial drugs. Ph.D. Thesis University of Navarra, Pamplona, Spain; 2010
   Google Scholar
• Martin del Valle EM. Cyclodextrins and their uses: a revies. Process Biochem 2004;39:1033-46
   Web of Science ®Google Scholar
• Terada Y, Yanase M, Takata H, Cyclodextrins are not the major cyclic alpha-1,4-glucans produced by the initial action of cyclodextrin glucanotransferase on amylose. J Biol Chem 1997;272:15729-33
   PubMed Web of Science ®Google Scholar
• Takaha T, Yanase M, Takata H, Potato D-enzyme catalyzes the cyclization of amylose to produce cycloamylose, a novel cyclic glucan. J Biol Chem 1996;271:2902-08
   PubMed Web of Science ®Google Scholar
• Astray G, Gonzalez-Barreiro C, Mejuto JC, A review on the use of cyclodextrins in foods. Food Hydrocol 2009;23:1631-40
   Web of Science ®Google Scholar
• Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving oral drug delivery. Am J Drug Del 2004;2:1-15
   Google Scholar
• Shimada K, Kawano K, Ishii J, Nakamura T. Structure of inclusion complexes of cyclodextrins with triglyceride at vegetable oil-water interface. J Food Sci 1992;57:655-56
   Web of Science ®Google Scholar
• Szejkli J. Past, present, and future of cyclodextrin research. Pure Appl Chem 2004;76:1825-45
   Web of Science ®Google Scholar
• Singh M, Sharma R, Banerjee UC. Biotechnological applications of cyclodextrins. Biotechnol Adv 2002;20:341-59
   PubMed Web of Science ®Google Scholar
• Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998;98:2045-76
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010;62:1607-21
   PubMed Web of Science ®Google Scholar
• Prabaharan M, Mano JF. Hydroxypropylchitosan bearing beta-cyclodextrin cavities: synthesis and slow release of its inclusion complex with a model hydrophobic drug. Macromol Biosci 2005;5:965-73
   PubMed Web of Science ®Google Scholar
• Bellanger N, Perly B. NMR investigations of the conformation of new cyclodextrin-based amphiphilic transporters for hydrophobic drugs - Molecular Lollipops. J Mol Struct 1992;273:215-26
   Web of Science ®Google Scholar
• Bilensoy E, Atilla HA. Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Exp Op Drug Del 2009;6:1161-73
   PubMed Web of Science ®Google Scholar
• Liu FY, Kildsig DO, Mitra AK. Complexation of 6-acyl-O-beta-cyclodextrin derivatives with steroids - Effects of chain-length and substitution degree. Drug Dev Ind Pharm 1992;18:1599-612
   Web of Science ®Google Scholar
• Roux M, Perly B, Djedaini-Pilard F. Self-assemblies of amphiphilic cyclodextrins. Eur Biophys J 2007;36:861-7
   PubMed Web of Science ®Google Scholar
• Zhang P, Ling CC, Coleman AW, Formation of amphiphilic cyclodextrins via hydrophobic esterification at the secondary hydroxyl face. Tetrahedron Lett 1991;32:2769-70
   Web of Science ®Google Scholar
• Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting: application to nanoparticles. Adv Drug Del Rev 1999;36:29-40
   PubMed Web of Science ®Google Scholar
• Wenz G. Synthesis and characterization of some lipophilic per(2,6-di-O-alkyl) cyclomalto-oligosaccharides. Carbohyd Res 1991;214:257-65
   Web of Science ®Google Scholar
• Wouessidjewe D, Skiba M, Leroy-Lechat F, A new concept in drug delivery based on ‘skirt-shaped cyclodextrin aggregates’ - Present state and future prospects. STP Pharma Sci 1996;6:21-8
   Google Scholar
• Fenyvesi F, Fenyvesi E, Szente L, P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci 2008;34:236-42
   PubMed Web of Science ®Google Scholar
• Yunomae K, Arima H, Hirayama F, Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. Febs Lett 2003;536:225-31
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, van Tellingen O, Schellens JHM, Beijnen JH. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest New Drug 2000;18:231-41
   PubMed Web of Science ®Google Scholar
• Schellens JHM, Malingre MM, Kruijtzer CMF, Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000;12:103-10
   PubMed Web of Science ®Google Scholar
• Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 2002;99:10347-52
   PubMed Web of Science ®Google Scholar
• Carrier RL, Miller LA, Ahmed M. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007;123:78-99
   PubMed Web of Science ®Google Scholar
• Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther 2001;297:547-55
   PubMed Web of Science ®Google Scholar
• van Waterschoot RAB, Rooswinkel RW, Wagenaar E, Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. Faseb J 2009;23(1):224-31
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90
   PubMed Web of Science ®Google Scholar
• van Herwaarden AE, Wagenaar E, van der Kruijssen CM, Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-92
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Yoshii H, Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotech Biochem 2005;69:246-8
   PubMed Web of Science ®Google Scholar
• McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo. Int J Pharm 1998;162:59-69
   Web of Science ®Google Scholar
• Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins and carrier systems. J Control Release 1999;62:263-8
   PubMed Web of Science ®Google Scholar
• Becirevic-Lacan M, Salko N. Hydrocortisone/cyclodextrin complex. Complexation methods and complex incorporation in liposomes. STP Pharma Sci 1997;7:343-47
   Google Scholar
• Loukas YL, Jayasekera P, Gregoriadis G. Characterization and photoprotection studies of a model gamma-cyclodextrin-included photolabile drug entrapped in liposomes incorporating light absorbers. J Phys Chem 1995;99:11035-40
   Web of Science ®Google Scholar
• Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001;225:15-30
   PubMed Web of Science ®Google Scholar
• Fatouros DG, Hatzidimitriou K, Antimisiaris SG. Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release. Eur J Pharm Sci 2001;13:287-96
   PubMed Web of Science ®Google Scholar
• Lira MCB, Ferraz MS, Silva DGVCd, Inclusion complex of usnic acid with beta-cyclodextrin: characterization and nanoencapsulation into liposomes. Incl Phenom Macrocycl Chem 2009;64:215-24
   Web of Science ®Google Scholar
• Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, Mura P. Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int J Pharm 2005;298:55-67
   PubMed Web of Science ®Google Scholar
• Gillet A, Grammenos A, Compere P, Development of a new topical system: drug-in-cyclodextrin-in-deformable liposome. Int J Pharm 2009;380:174-80
   PubMed Web of Science ®Google Scholar
• Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, New ‘drug-in cyclodextrin-in deformable liposomes’ formulations to improve the therapeutic efficacy of local anaesthetics. Int J Pharm 2010;395:222-31
   PubMed Web of Science ®Google Scholar
• Boudad H, Legrand P, Lebas G, Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 2001;218:113-24
   PubMed Web of Science ®Google Scholar
• Mooguee M, Omidi Y, Davaran S. Synthesis and in vitro release of adriamycin from star-shaped poly(lactide-co-glycolide) nano- and microparticles. J Pharm Sci 2010;99:3389-97
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang C, Liang XJ, Hydroxypropyl-beta-cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system. J Pharm Sci 2010;100:1067-79
   Google Scholar
• Jerry N, Anitha Y, Sharma CP, Sony P. In vivo absorption studies of insulin from an oral delivery system. Drug Deliv 2001;8:19-23
   PubMed Web of Science ®Google Scholar
• Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev 1999;36:101-23
   PubMed Web of Science ®Google Scholar
• Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 2006;325:147-54
   PubMed Web of Science ®Google Scholar
• Zhang N, Li J, Jiang W, Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm 2010;393:212-18
   PubMed Web of Science ®Google Scholar
• Trapani A, Garcia-Fuentes M, Alonso MJ. Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 2008;19:185101
   PubMedGoogle Scholar
• Trapani A, Lopedota A, Franco M, A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur J Pharm Biopharm 2010;75:26-32
   PubMed Web of Science ®Google Scholar
• Arbos P, Wirth M, Arangoa MA, Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J Control Release 2002;83:321-30
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6th edition. Pharmaceutical Press; North Yorkshire, UK; 2009
   Google Scholar
• Arbos P, Campanero MA, Arangoa MA, Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release 2003;89:19-30
   PubMed Web of Science ®Google Scholar
• Ojer P, Salman H, Martins RDC, Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery. J Drug Del Sci Technol 2010;20:353-59
   Web of Science ®Google Scholar
• Agueros M, Areses P, Campanero MA, Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 2009;37:231-40
   PubMed Web of Science ®Google Scholar
• Arangoa MA, Campanero MA, Renedo MJ, Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res 2001;18:1521-7
   PubMed Web of Science ®Google Scholar
• Arbos P, Arangoa MA, Campanero MA, Irache JM. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles. Int J Pharm 2002;242:129-36
   PubMed Web of Science ®Google Scholar
• Areses P, Agueros MT, Quincoces G, Molecular imaging techniques to study the biodistribution of orally administered (99m)Tc-labelled naive and ligand-tagged nanoparticles. Mol Imaging Biol 16 Dec 2010 [Epub ahead of print]
   Google Scholar
• Agueros M, Ruiz-Gaton L, Vauthier C, Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009;38:405-13
   PubMed Web of Science ®Google Scholar
• Jain R, Agarwal S, Majumdar S, Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int J Pharm 2005;303:8-19
   PubMed Web of Science ®Google Scholar
• Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G. Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm 2008;69:436-44
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516-30
   PubMed Web of Science ®Google Scholar
• Mardones P, Andrinolo D, Csendes A, Lagos N. Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique. Toxicon 2004;44:521-8
   PubMed Web of Science ®Google Scholar
• Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004;21:261-70
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch M, Warner E. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;24:110-15
   Google Scholar
• Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455-65
   PubMed Web of Science ®Google Scholar
• Weingart SN, Brown E, Bach PB, NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008;6:S1-14
   PubMedGoogle Scholar
• Terwogt JM, Schellens JH, Huinink WW, Beijnen JH. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 1999;25:83-101
   PubMed Web of Science ®Google Scholar
• Irshad S. Considerations when choosing oral chemotherapy: identifying and responding to patient need. Eur J Cancer Care 2010;19:5-11
   PubMed Web of Science ®Google Scholar
• Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007;59:1482-503
   PubMed Web of Science ®Google Scholar
• Lo YL. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 2003;90:37-48
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130:98-106
   PubMed Web of Science ®Google Scholar
• Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 2002;91:1980-90
   PubMed Web of Science ®Google Scholar